We investigated whether IL12 protein could be delivered to ideal tumor sites by adoptive transfer of GPC3-Syn-IL12-NK92 cells and determined the immune-stimulatory properties of IL12 delivered by GPC3-Syn-IL12-NK92 cells to improve the antitumor ability of GPC3-specific CAR-T cells, with the aim of developing a safe and accurate cytokine administration for tumor treatment. The gene discussed is GPC3; the disease is neoplasm.